235 related articles for article (PubMed ID: 26080733)
1. Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
Liu J; Peng X; Dai Y; Zhang W; Ren S; Ai J; Geng M; Li Y
Org Biomol Chem; 2015 Jul; 13(28):7643-54. PubMed ID: 26080733
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.
Zhang Z; Zhao D; Dai Y; Cheng M; Geng M; Shen J; Ma Y; Ai J; Xiong B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27782099
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel 1
Liu J; Wen Y; Gao L; Gao L; He F; Zhou J; Wang J; Dai R; Chen X; Kang D; Hu L
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):72-84. PubMed ID: 31682465
[TBL] [Abstract][Full Text] [Related]
4. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.
Cui J; Peng X; Gao D; Dai Y; Ai J; Li Y
Bioorg Med Chem Lett; 2017 Aug; 27(16):3782-3786. PubMed ID: 28687204
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.
Liu J; Qian C; Zhu Y; Cai J; He Y; Li J; Wang T; Zhu H; Li Z; Li W; Hu L
Bioorg Med Chem; 2018 Feb; 26(3):747-757. PubMed ID: 29317150
[TBL] [Abstract][Full Text] [Related]
6. Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1480-3. PubMed ID: 21288717
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of Rho kinase inhibitors (II).
Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.
Yan W; Wang X; Dai Y; Zhao B; Yang X; Fan J; Gao Y; Meng F; Wang Y; Luo C; Ai J; Geng M; Duan W
J Med Chem; 2016 Jul; 59(14):6690-708. PubMed ID: 27348537
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and preliminary biological evaluation of C-8 substituted guanine derivatives as small molecular inhibitors of FGFRs.
Ye F; Chen L; Hu L; Xiao T; Yu S; Chen D; Wang Y; Liang G; Liu Z; Wang S
Bioorg Med Chem Lett; 2015 Apr; 25(7):1556-60. PubMed ID: 25736993
[TBL] [Abstract][Full Text] [Related]
10. Indazoles as potential c-Met inhibitors: design, synthesis and molecular docking studies.
Ye L; Ou X; Tian Y; Yu B; Luo Y; Feng B; Lin H; Zhang J; Wu S
Eur J Med Chem; 2013 Jul; 65():112-8. PubMed ID: 23702473
[TBL] [Abstract][Full Text] [Related]
11. Fragment-based design, synthesis, biological evaluation, and SAR of 1H-benzo[d]imidazol-2-yl)-1H-indazol derivatives as potent PDK1 inhibitors.
Chen T; Sorna V; Choi S; Call L; Bearss J; Carpenter K; Warner SL; Sharma S; Bearss DJ; Vankayalapati H
Bioorg Med Chem Lett; 2017 Dec; 27(24):5473-5480. PubMed ID: 29150397
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W
Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors.
Hou S; Yang X; Yang Y; Tong Y; Chen Q; Wan B; Wei R; Lu T; Chen Y; Hu Q
Eur J Med Chem; 2021 Aug; 220():113482. PubMed ID: 33906048
[TBL] [Abstract][Full Text] [Related]
15. Discovery of inhibitors of the mitotic kinase TTK based on N-(3-(3-sulfamoylphenyl)-1H-indazol-5-yl)-acetamides and carboxamides.
Laufer R; Ng G; Liu Y; Patel NK; Edwards LG; Lang Y; Li SW; Feher M; Awrey DE; Leung G; Beletskaya I; Plotnikova O; Mason JM; Hodgson R; Wei X; Mao G; Luo X; Huang P; Green E; Kiarash R; Lin DC; Harris-Brandts M; Ban F; Nadeem V; Mak TW; Pan GJ; Qiu W; Chirgadze NY; Pauls HW
Bioorg Med Chem; 2014 Sep; 22(17):4968-97. PubMed ID: 25043312
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Pastor RM; Burch JD; Magnuson S; Ortwine DF; Chen Y; De La Torre K; Ding X; Eigenbrot C; Johnson A; Liimatta M; Liu Y; Shia S; Wang X; Wu LC; Pei Z
Bioorg Med Chem Lett; 2014 Jun; 24(11):2448-52. PubMed ID: 24767842
[TBL] [Abstract][Full Text] [Related]
17. Indazole Derivatives: Promising Anti-tumor Agents.
Wan Y; He S; Li W; Tang Z
Anticancer Agents Med Chem; 2018; 18(9):1228-1234. PubMed ID: 29745343
[TBL] [Abstract][Full Text] [Related]
18. Scaffold oriented synthesis. Part 3: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing [2+3] cycloadditions.
Akritopoulou-Zanze I; Wakefield BD; Gasiecki A; Kalvin D; Johnson EF; Kovar P; Djuric SW
Bioorg Med Chem Lett; 2011 Mar; 21(5):1476-9. PubMed ID: 21282054
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
[TBL] [Abstract][Full Text] [Related]
20. Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity.
Chen Z; Wang X; Zhu W; Cao X; Tong L; Li H; Xie H; Xu Y; Tan S; Kuang D; Ding J; Qian X
J Med Chem; 2011 Jun; 54(11):3732-45. PubMed ID: 21517068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]